Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163071 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01163071 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 60 participants.
The verdict
NCT01163071, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
Interventions
- DRUG ABI-011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-03-01 |
| Est. Completion | 2011-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163071
The ClinicalTrials.gov registry entry for NCT01163071 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-011 is the first listed.
NCT01163071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163071 about?
NCT01163071 is a clinical study titled "A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas". The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
What is the current status of trial NCT01163071?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-03-01. Estimated completion is 2011-09-23.
What interventions are being tested in trial NCT01163071?
The interventions under investigation include: ABI-011 (DRUG).
Who is sponsoring clinical trial NCT01163071?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.